Fol. Biol. 2003, 49, 217-222
https://doi.org/10.14712/fb2003049060217
Adjuvant Cytokine Treatment of Minimal Residual Disease after Surgical Therapy in Mice Carrying HPV16-Associated Tumours: Cytolytic Activity of Spleen Cells from Tumour Regressors
References
1. , J. (2002) Animal models for development of therapeutic HPV16 vaccines. Int. J. Oncol. 20, 207-212.
2. , J. (2003) MHC class I downregulation and tumour immunotherapy. Oncol. Rep. 10, 2005-2008.
3. , J., Lotzová, E., Indrová, M. Šímová, J., Jandlová, T., Bubeníková, D. (1992) Use of IL-2 gene transfer in local immunotherapy of cancer. Cancer Lett. 62, 257-262.
<https://doi.org/10.1016/0304-3835(92)90104-4>
4. , J., Zeuthen J., Indrová, M., Bubeníková, D., Šímová, J. (1994) Kinetics and function of peritoneal exudate cells during local IL-2 gene therapy of cancer. Int. J. Oncol. 4, 13-16.
5. , J., Šímová, J., Hájková, R., Sobota, V., Jandlová, T., Šmahel, M., Sobotková. E., Vonka, V. (1999) Interleukin-2 gene therapy of residual disease in mice carrying tumours induced by HPV 16. Int. J. Oncol. 14, 593-597.
6. , J., Mikyšková, R., Vonka, V., Mendoza, L., Šímová, J., Šmahel, M., Indrová, M. (2003) Interleukin 2 and dendritic cells as adjuvants for surgical therapy of tumours associated with human papilloma virus type 16. Vaccine 21, 890-896.
<https://doi.org/10.1016/S0264-410X(02)00537-6>
7. , H., Butler, C. H., Anderson, M. M. (1953) Growth characteristic of free C1498 (granulocytic leukaemia) tumour cells in the peritoneal fluid and the blood of C57 mice. Cancer Res. 13, 125-129.
8. , M., Bubeník, J., Šímová, J., Bieblová, J., Jandlová, T., Šmahel, M., Vonka, V., Glazman-Kusnierczyk, H., Pajtasz-Piasecka, E., Radzikowski, C., Mikyšková, R. (2001) Chemoimmunotherapy of cancer: potentiated effectiveness of granulocyte-macrophage colony-stimulating factor and ifosfamide derivative CBM-4A. Oncol. Rep. 8, 1371-1374.
9. , M., Bubeník, J., Mikyšková, R., Vonka, V., Šmahel, M., Žák, R., Šímová, J., Bieblová, J., Mendoza, L., Jandlová, T. (2002) Tumour inhibitory and antimetastatic effect of IL-2 in mice carrying MHC class I tumours of HPV 16 origin. Int. J. Oncol. 20, 643-646.
10. , M., Bubeník, J., Mikyšková, R., Mendoza, L., Šímová, J., Bieblová, J., Jandlová, T., Jinoch, P., Šmahel, M., Vonka, V., Pajtasz-Piasecka, E. (2003) Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class Iñ tumours: effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines. Int. J. Oncol. 22, 691-695.
11. , P., Žák, R., Janoušková, O., Kunke, O., Ritich, S., Dušková, M., Sobotková, E., Marinov, I., Andělová, M., Šmahel, M., Vonka, V. (2003) Immunization with live HPV-16-transformed mouse cells expressing the herpes simplex thymidine-kinase and either GM-CSF or IL-2. Int. J. Oncol. 23, 775-783.
12. , J. L., Truit, R. L. (2002) Characterization of murine NKT cell tumor previously described as an acute myelogenous leukemia. Leuk. Lymphoma 43, 1637-1644.
<https://doi.org/10.1080/1042819021000002974>
13. , K. Y., Guarnieri, F. G., Staveley O'Carroll, K. F., Levitsky, H. J., August, J. T., Pardoll, D. M., Wu, T. C. (1996) Treatment of established tumours with a novel vaccine that enhances major histocompatibility class II presentation of tumour antigen. Cancer Res. 56, 21-26.
14. , R., Bubeník, J., Mendoza, L., Vonka, V., Šmahel, M., Šímová, J., Jandlová, T. (2001) Local cytokine treatment of HPV16-associated tumours results in inhibition of their lung metastases. Clin. Exp. Metastasis 18, 581-587.
<https://doi.org/10.1023/A:1011987206008>
15. , R., Bieblová, J., Šímová, J., Indrová, M., Jandlová, T., Vonka, V., Šmahel, M., Bubeník, J., Mendoza, L. (2003a) Local IFNγ therapy of HPV16-associated tumours. Folia Biol. (Praha) 49, 26-32.
16. Mikyšková, R., Indrová, M. Šímová, J., Jandlová, T., Bieblová, J., Jinoch J., Bubeník, J., Vonka, V. (2003b) Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16-associated tumours: cytokine and gene therapy with IL-2 and GMCSF. Int. J. Oncol., in press.
17. , R., van der Burg, S. H., Ossendorp, F., Toes, R. E., Melief, C. J. (2000) Design and evaluation of antigen-specific vaccination strategies against cancer. Curr. Opin. Immunol. 12, 576-582.
<https://doi.org/10.1016/S0952-7915(00)00145-X>
18. , M., Sobotková, E., Bubeník, J., Šímová, J., Žák, R., Ludvíková, V., Hájková, R., Kovařík, J., Jelínek, F., Povýšil, C., Marinov, J., Vonka, V. (2001) Metastatic MHC class I-negative mouse cells derived by transformation with human papillomavirus type 16. Br. J. Cancer 84, 374-380.
<https://doi.org/10.1054/bjoc.2000.1615>
19. , V., Rössner, P., Indrová, M., Bubeník, J., Sobota, V. (1998) Interleukin-2 gene therapy of surgical minimal residual tumour disease. Int. J. Cancer 76, 115-119.
<https://doi.org/10.1002/(SICI)1097-0215(19980330)76:1<115::AID-IJC18>3.0.CO;2-B>
20. Wigzell, H., Ramstedt, U. (1986) Natural killer cells. In: Cellular Immunology, ed. Weir, M. M., pp. 601-609, Blackwell Scientific Publ., Oxford.
